Pantoprazole
Unchecked
Pantoprazole
Protonix
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Pharmacy
Starting dose
40 mg PO or IV once daily
Preparations
20 mg, 40 mg delayed-release tablets; 40 mg IV vial; oral suspension 40 mg/packet
US FDA Max
40 mg/d typical; up to 240 mg/d for Zollinger-Ellison
Pharmacology
Routes
Oral, IV
Onset
2-3 hours per dose; full acid suppression after 3-5 days
Duration
24+ hours (irreversible enzyme binding)
Half-life
~1 hour (plasma); pharmacodynamic effect persists 24+ hours[2]
Bioavailability
~77% (oral; not affected by food or antacids)[2]
Pregnancy
Generally considered safe; widely used in obstetric reflux.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Pantoprazole is a prodrug irreversibly bound to the H+/K+ ATPase after acid-driven activation, blocking the final common step of gastric acid secretion.0 Compared with omeprazole, pantoprazole has a more linear pharmacokinetic profile and is metabolized predominantly via CYP2C19 with CYP3A4 contribution; less CYP2C19-driven drug interaction with clopidogrel than omeprazole[1].
References
[edit | edit source]- ↑ CPIC Guideline for CYP2C19 and Proton Pump Inhibitors, 2020. https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/
- ↑ 2.0 2.1 FDA Prescribing Information, Protonix (pantoprazole sodium), Pfizer, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020987s045,022020s016lbl.pdf